ClinicalTrials.gg
RecruitingNCT05174052Updated Apr 1, 2026

Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

A Phase 3 interventional study of Dapagliflozin 10Mg Tab and Placebo in Diabetes Mellitus and Atrial Fibrillation, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by University of Oklahoma · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies testing dapagliflozin in Diabetes Mellitus — 8 open to participants now, 10 under way, 4 of them phase 3. dapagliflozin · Diabetes Mellitus.

Planned enrollment
45th of 51
28 · median 80
Started
2022
with 3 others
Phase 3
16 of 51
2 open now
Registered
33rd of 51
by date

Among the 51 studies testing dapagliflozin in Diabetes Mellitus, this one is the 45th largest by planned enrollment, is one of 4 that started in 2022, is one of 16 in phase 3, and was the 33rd registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

8 of the 51 studies testing dapagliflozin in Diabetes Mellitus are open now, in 7 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing dapagliflozin in Diabetes Mellitus, or all of them as a file.
02

Study summary

The study will investigate the effect of Dapagliflozin on atrial fibrillation (AF) burden. AF burden will be defined as the percent of time spent in AF over a 2-week period, assessed by noninvasive continuous heart rhythm monitoring at baseline and at 3 months, quality of life (QOL) and validated echocardiographic indices of atrial myopathy. This knowledge will enable us to study the therapeutic potential of SGLT2i as a novel adjunct treatment for patients with DM and AF. Patients with paroxysmal AF (AF that terminates spontaneously or with intervention within seven days of onset) and DM and randomize them to Dapagliflozin or placebo. Continuous heart rhythm monitoring patch for AF burden will be used, measure of QOL with the help of AF Effect on Quality-of-life survey and perform an echocardiogram with measurement of left atrial volume index, left atrial strain and atrial tissue dopplers. All measurements will be performed at baseline and at study completion. The central hypothesis is that SGLT2i will lead to reduced AF burden that will translate into improvement in QOL, and the underlying mechanism is improvement in atrial myopathy.

Read the detailed description

Patients with diabetes mellitus (DM) and atrial fibrillation (AF) represent a high-risk cohort that is at an increased risk of cardiovascular complications as compared to AF patients without DM. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new class of diabetic drugs and large clinical trials have established their multiple cardiovascular benefits. However, none of these clinical trials studied AF as a primary outcome. SGLT2i have multiple properties that can be protective against AF and the role of SGLT2i in preventing recurrent AF remains an important knowledge gap.

In this translational research proposal, we aim to fill this knowledge gap by studying the effect of Dapagliflozin on AF burden. AF burden will be defined as the percent of time spent in AF over a 2-week period, assessed by noninvasive continuous heart rhythm monitoring at baseline and at 3 months, quality of life (QOL) and validated echocardiographic indices of atrial myopathy. This knowledge will enable us to study the therapeutic potential of SGLT2i as a novel adjunct treatment for patients with DM and AF. Patients with paroxysmal AF (AF that terminates spontaneously or with intervention within seven days of onset) and DM will be enrolled. Subjects will be randomized to Dapagliflozin or placebo. Continuous heart rhythm monitoring patch for AF burden, measure QOL with the help of AF Effect on Quality-of-life survey and perform an echocardiogram with measurement of left atrial volume index, left atrial strain and atrial tissue dopplers. All measurements will be performed at baseline and at study completion. Our central hypothesis is that SGLT2i will lead to reduced AF burden that will translate into improvement in QOL, and the underlying mechanism is improvement in atrial myopathy.

03

Conditions studied

  • Diabetes Mellitus
  • Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with DM
  • Paroxysmal AF

Exclusion criteria

Exclusion Criteria:

  • Type 1 DM,
  • Symptoms of hypotension or systolic blood pressure \<90mmHg,
  • Severe renal impairment with \<30mL/minute/1.73m2,
  • History of lower limb amputation,
  • to Dapagliflozin,
  • Currently taking any SGLT2i,
  • Pregnancy,
  • Currently taking anti-arrhythmic drugs
  • Undergoing catheter ablation will be excluded
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Placebo comparator
    Control Arm (Placebo)

    Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme.

    Drug: Placebo

  • Active comparator
    Intervention Arm (Dapagliflozin)

    A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme

    Drug: Dapagliflozin 10Mg Tab

Interventions

  • DrugDapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.

  • DrugPlacebo

    Subjects will take 1 blinded capsule of placebo drug dosed once daily

06

What researchers measure

Primary outcomes

  1. The effect of Dapagliflozin on change in burden of atrial fibrillation

    To determine the effect of Dapagliflozin on change in AF burden in patients with AF and DM. AF burden will be defined as the percent of time spent in AF over a 2-week period, assessed by noninvasive continuous heart rhythm monitoring at baseline and at 3 months. The AF burden between Dapagliflozin vs Placebo will be compared.

    Time frame: Baseline and 3 months

Secondary outcomes

  1. Effect of Dapagliflozin on change in AF Effect on Quality of Life Survey

    To determine the effect of Dapagliflozin on change in quality of life in patients with AF and DM. AF Effect on Quality of Life Survey will be used to compare QOL between Dapagliflozin vs Placebo.

    Time frame: Baseline and 3 months

Other outcomes

  1. Effect of Dapagliflozin on change in Validated Echocardiographic Indices & Biomarkers of Atrial Myopathy

    To determine the effect of Dapagliflozin on validated echocardiographic indices and biomarkers of atrial myopathy in patients with AF and DM. We will compare left atrial volume index (ml/m2), left atrial strain and atrial tissue dopplers (cm/s). All measurements will be performed at baseline and at study completion and compared between Dapagliflozin vs Placebo. We will measure brain natriuretic peptide and other biomarkers as well.

    Time frame: Baseline and 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Apr 2027, 58 months after the start.

Of 63 non-industry phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 79. This study's planned 58 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2021
First posted
Dec 30, 2021
StartActual
Jun 1, 2022
Primary completionEst.
Apr 2027
CompletionEst.
Dec 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05174052
Responsible party
Sponsor
First posted
Dec 30, 2021
Start date
Jun 1, 2022
Primary completion
Apr 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 1, 2026

Study contacts

Aurora Vera
Contact
Aurora-Vera@ouhsc.edu
405-271-8001 ext. 45319
Natalia Wells-Serrano
Contact
natalia-wellsserrano@ouhsc.edu
405-271-4742
Zain Ul Abideen Asad, MD
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion